Rodman & Renshaw Cuts Rexahn Pharma (RNN) to Market Perform
Tweet
Share
E-mailGet Alerts RNN Hot Sheet
Price: $5.24 --0%
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Rodman & Renshaw's Elemer Piros downgraded shares of Rexahn Pharma (NYSE: RNN) from Market Outperform to Market Perform.
The stock is up nearly 17 percent at last check amid European approval to conduct a first-in-human trial for its RX-3117.
For an analyst ratings summary and ratings history on Rexahn Pharma click here. For more ratings news on Rexahn Pharma click here.
The stock is up nearly 17 percent at last check amid European approval to conduct a first-in-human trial for its RX-3117.
For an analyst ratings summary and ratings history on Rexahn Pharma click here. For more ratings news on Rexahn Pharma click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades AAC Technologies Holdings Inc. (2018:HK) (AACAY) to Neutral
- JPMorgan Downgrades Bowman Consulting Group Ltd. (BWMN) to Underweight
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
Create E-mail Alert Related Categories
DowngradesRelated Entities
Rodman & RenshawSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
